肠道菌群对肝细胞癌的影响:发病机制、诊断、预后及治疗前景
本综述阐述肠道菌群通过肠-肝轴参与肝细胞癌(HCC)发生与抑制的双向作用,并影响宿主代谢与免疫从而调节治疗反应和预后。文章强调肠道菌群作为HCC诊断与预后预测的新型生物标志物的潜力,并汇总其与手术、化疗、放疗、免疫治疗及靶向药物疗效的关系,探讨益生菌、粪菌移植(FMT)和饮食调整等微生物组靶向干预作为新兴辅助策略。
要点
- 肠道菌群失调通过肠-肝轴参与HCC的促进与抑制。
- 肠道菌群影响HCC治疗反应与预后结局。
- 益生菌、FMT和饮食调整是新兴辅助干预策略。
核心结论
- 肠道菌群通过肠-肝轴及与宿主代谢和免疫的相互作用,在HCC发生发展、诊断、预后和治疗反应中发挥重要作用。
研究设计与样本
- 本综述总结肠道菌群与HCC相互作用的分子机制及现有认识。
主要发现
- 肠道菌群失调与HCC的促进和抑制均有关。
- 肠道菌群通过宿主代谢与免疫互作显著影响HCC治疗反应和预后。
- 肠道菌群有潜力作为HCC诊断和预后预测的新型生物标志物。
- 肠道菌群与手术、化疗、放疗、免疫治疗及靶向药物等多种治疗的疗效相关。
临床怎么用
- 可关注肠道菌群作为HCC诊断与预后预测生物标志物的潜力。
- 益生菌、粪菌移植和饮食改变可作为新兴辅助策略用于HCC管理。
- 理解肠道菌群与各治疗手段疗效的关系有助于制定个体化治疗策略。
局限性
- 尽管取得进展,相关挑战仍然存在。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Advances in sequencing technology have elucidated the complex role of the gut microbiota in hepatocellular carcinoma (HCC). Communication between the gut and the liver occurs via the gut-liver axis, and dysbiosis of the gut microbiota has been implicated in both the promotion and suppression of HCC. Furthermore, through interactions with host metabolism and immune system, the gut microbiota significantly influences treatment responses and prognostic outcomes of HCC. Despite progress in therapeutic strategies, clinical efficacy remains suboptimal, underscoring the need for a deeper understanding of the gut microbiota's role. This review highlights the potential of gut microbiota as novel biomarkers for the diagnosis and prognostic prediction of HCC, and explores its therapeutic implications. We summarize current insights into the molecular mechanisms underlying the gut microbiota-HCC interplay, and emphasize the relationship between gut microbiota and the efficacy of various treatments, including surgery, chemotherapy, radiotherapy, immunotherapy, and targeted agents. Microbiome-targeting interventions like probiotics, fecal microbiota transplantation (FMT), and dietary changes as emerging adjuvant strategies are also discussed in detail to provide potential resources for advancing translational hepatology. Although challenges remain, this review aims to provide valuable perspectives for developing individualized therapeutic strategies in HCC management.
引用
- Chen Q, Feng X, Wang J, et al. Impact of gut microbiota on hepatocellular carcinoma: Pathogenesis, diagnosis, prognosis, and therapeutic prospective. Eur J Cancer. 2026. PMID: 41785672. doi:10.1016/j.ejca.2026.116581
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。